ArticleDiscover oncology2025
Identification of Gαi1 as a key regulator of tumor progression in nasopharyngeal carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThe G protein α inhibitory subunit 1 (Gαi1) has been implicated in cancer progression. This study investigates its role in nasopharyngeal carcinoma (NPC), focusing on its expression, clinical relevance, and molecular mechanisms.
methodsThe expression level and prognostic value of Gαi1 were evaluated based on public databases, and further confirmed in NPC tissues and cells by western blot analysis, quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC). Functional assays, including Gαi1 knockdown in NPC cell lines, assessed its effects on proliferation, migration, invasion, apoptosis, and signaling. The Gαi1-SETD7 interaction was explored to elucidate underlying mechanisms.
resultsGαi1 was upregulated in tumor tissues, with the highest expression in head and neck squamous cell carcinoma (HNSCC). Elevated Gαi1 levels correlated with poor prognosis and increased metastasis. In NPC, Gαi1 overexpression was confirmed at both mRNA and protein levels. Gαi1 knockdown reduced cell cycle progression, ERK and Akt-mTOR signaling, inhibited cell proliferation, migration, and invasion, and promoted apoptosis. In vivo, Gαi1 silencing suppressed tumor growth. Moreover, Gαi1 regulated SETD7 expression, with SETD7 overexpression rescuing the effects of Gαi1 knockdown.
conclusionGαi1 promotes tumor progression in NPC through the cell cycle, ERK and Akt-mTOR pathway and by regulating SETD7. Targeting Gαi1 or its signaling may offer a novel therapeutic strategy for NPC and potentially other cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.